{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:30:45Z","timestamp":1792557045895,"version":"4.5.0"},"reference-count":58,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"unspecified","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/CRTF\/22\/24395"],"award-info":[{"award-number":["FS\/CRTF\/22\/24395"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,20]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>A quarter of breast cancers show human epidermal growth factor-2 (HER2) overexpression, where targeted therapy dramatically improves survival. However, cancer therapy-related cardiac dysfunction (CTRCD) occurs in up to 15% of patients. With the interruption of HER2 therapy, if necessary, and the initiation of heart failure therapy (HFT), HER2 CTRCD recovers in over 80% of cases. The need to continue HFT in \u2018recovered\u2019 HER2 CTRCD following completion of HER2 therapy is unclear and there are potential significant impacts on patient\u2019s quality of life (QoL). The Randomised Controlled Trial for the Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction (HER-SAFE) aims to evaluate whether HFT can be safely withdrawn in non-high cardiovascular (CV) risk patients with \u2018recovered\u2019 HER2 CTRCD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a multicentre, open-label randomised controlled trial investigating whether withdrawal of HFT is non-inferior to continuation in non-high CV risk, breast cancer survivors with recovered HER2 CTRCD after cancer treatment completion. The primary endpoint is the incidence of guideline-defined cardiac dysfunction or clinical heart failure. Secondary endpoints include changes in cardiac blood biomarkers, cardiovascular magnetic resonance (CMR)-derived strain and tissue mapping and heart failure symptom questionnaires. The study will recruit 90 participants who will undergo serial clinical assessment over 12 months with advanced cardiovascular imaging (CMR scans with automated analysis at baseline, 6 and 12 months), cardiac biomarker measurement (six time points over 12 months), plus complete heart failure QoL and medication disutility questionnaires. This is the first multicentre study to address this significant clinical issue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study was approved by the research ethics committee (London\u2014London Bridge, 23\/LO\/0152). The results will be disseminated in peer-reviewed scientific journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05880160\">NCT05880160<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-091917","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T05:21:37Z","timestamp":1738732897000},"page":"e091917","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related cardiac dysfunction"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05880160","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05880160","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05880160","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06091475","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06183437","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06183437","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8877-0629","authenticated-orcid":false,"given":"Benjamin","family":"Dowsing","sequence":"first","affiliation":[{"name":"Institute of Cardiovascular Science, University College London, London, UK"},{"name":"Saint Bartholomew's Hospital Barts Heart Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim-Moulay","family":"Dehbi","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit at UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Chung","sequence":"additional","affiliation":[{"name":"Saint Bartholomew's Hospital Barts Heart Centre, London, UK"},{"name":"Whittington Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Pedra","sequence":"additional","affiliation":[{"name":"Saint Bartholomew's Hospital Barts Heart Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orla","family":"Worn","sequence":"additional","affiliation":[{"name":"Saint Bartholomew's Hospital Barts Heart Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Artico","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London, London, UK"},{"name":"Imperial College Healthcare NHS Trust Cardiology Service, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schmid","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, UK"},{"name":"Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Roylance","sequence":"additional","affiliation":[{"name":"Department of Oncology, UCLH Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kellman","sequence":"additional","affiliation":[{"name":"National Heart Lung and Blood Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C","family":"Moon","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London, London, UK"},{"name":"Saint Bartholomew's Hospital Barts Heart Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Crake","sequence":"additional","affiliation":[{"name":"Saint Bartholomew's Hospital Barts Heart Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Westwood","sequence":"additional","affiliation":[{"name":"Saint Bartholomew's Hospital Barts Heart Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London, London, UK"},{"name":"Saint Bartholomew's Hospital Barts Heart Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sol","family":"Andres","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Centre of Excellence, Royal Brompton Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhummad Sohaib","family":"Nazir","sequence":"additional","affiliation":[{"name":"King's College London School of Biomedical Engineering & Imaging Sciences, London, UK"},{"name":"Cardio-Oncology Centre of Excellence, Royal Brompton and Harefield Hospitals, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R","family":"Lyon","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Centre of Excellence, Royal Brompton Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London, London, UK"},{"name":"Saint Bartholomew's Hospital Barts Heart Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Walker","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte H","family":"Manisty","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London, London, UK"},{"name":"Saint Bartholomew's Hospital Barts Heart Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"2025120619231242000_15.2.e091917.1","unstructured":"Breast cancer statistics . World cancer research fund international. Available: https:\/\/www.wcrf.org\/cancer-trends\/breast-cancer-statistics\/ [Accessed 29 Apr 2024]."},{"key":"2025120619231242000_15.2.e091917.2","unstructured":"Cancer Registration Statistics . England 2019 - NHS digital. Available: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/cancer-registration-statistics\/england-2019\/content [Accessed 16 Jan 2022]."},{"key":"2025120619231242000_15.2.e091917.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.2470152"},{"key":"2025120619231242000_15.2.e091917.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"key":"2025120619231242000_15.2.e091917.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910383"},{"key":"2025120619231242000_15.2.e091917.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.014"},{"key":"2025120619231242000_15.2.e091917.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.3.719"},{"key":"2025120619231242000_15.2.e091917.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.09.001"},{"key":"2025120619231242000_15.2.e091917.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"2025120619231242000_15.2.e091917.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw211"},{"key":"2025120619231242000_15.2.e091917.11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0044"},{"key":"2025120619231242000_15.2.e091917.12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa006"},{"key":"2025120619231242000_15.2.e091917.13","first-page":"1","article-title":"Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer","volume":"6","author":"Sardesai","year":"2020","journal-title":"Cardiooncology"},{"key":"2025120619231242000_15.2.e091917.14","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/jnci\/djaa054","article-title":"Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada","volume":"112","author":"Rushton","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2025120619231242000_15.2.e091917.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.9288"},{"key":"2025120619231242000_15.2.e091917.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.827"},{"key":"2025120619231242000_15.2.e091917.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1215"},{"key":"2025120619231242000_15.2.e091917.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0463"},{"key":"2025120619231242000_15.2.e091917.19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10557-021-07181-3","article-title":"The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review","volume":"36","author":"Wu","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"2025120619231242000_15.2.e091917.20","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000013839.41224.1C"},{"key":"2025120619231242000_15.2.e091917.21","first-page":"1080","article-title":"Outcomes of Spironolactone Withdrawal in Dilated Cardiomyopathy With Improved Ejection Fraction","volume":"8","author":"Chen","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2025120619231242000_15.2.e091917.22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"The Lancet"},{"key":"2025120619231242000_15.2.e091917.23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2025120619231242000_15.2.e091917.24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ejhf.2063","article-title":"Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TRED-HF","volume":"23","author":"Halliday","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025120619231242000_15.2.e091917.25","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1920"},{"key":"2025120619231242000_15.2.e091917.26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ehf2.13133","article-title":"Late gadolinium enhancement for re-worsening left ventricular ejection fraction in patients with dilated cardiomyopathy","volume":"8","author":"Nabeta","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2025120619231242000_15.2.e091917.27","unstructured":"Female breast cancer \u2014 cancer stat facts. Available: https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html [Accessed 2 Jul 2024]."},{"key":"2025120619231242000_15.2.e091917.28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/eurjcn\/zvab057","article-title":"Quality of life in breast cancer patients with cancer treatment-related cardiac dysfunction: a qualitative study","volume":"21","author":"Koop","year":"2022","journal-title":"Eur J Cardiovasc Nurs"},{"key":"2025120619231242000_15.2.e091917.29","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jaccao.2020.08.010","article-title":"How to Follow, Manage and Treat Cardiac Dysfunction in Patients With Her2+ Breast Cancer","volume":"2","author":"Blaes","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2025120619231242000_15.2.e091917.30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.007595"},{"key":"2025120619231242000_15.2.e091917.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063800","article-title":"Quantifying the impact of taking medicines for primary prevention: a time-trade off study to elicit direct treatment disutility in the UK","volume":"13","author":"Thompson","year":"2023","journal-title":"BMJ Open"},{"key":"2025120619231242000_15.2.e091917.32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(07)61835-2","article-title":"CONSORT for reporting randomised trials in journal and conference abstracts","volume":"371","author":"Hopewell","year":"2008","journal-title":"The Lancet"},{"key":"2025120619231242000_15.2.e091917.33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"2025120619231242000_15.2.e091917.34","unstructured":"NICE . Recommendations | hypertension in adults: diagnosis and management | guidance | 2019."},{"key":"2025120619231242000_15.2.e091917.35","doi-asserted-by":"crossref","first-page":"734","DOI":"10.4236\/jbise.2011.411090","article-title":"Implementation of an open-source customizable minimization program for allocation of patients to parallel groups in clinical trials","volume":"04","author":"Saghaei","year":"2011","journal-title":"J Biomed Sci Eng"},{"key":"2025120619231242000_15.2.e091917.36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab674"},{"key":"2025120619231242000_15.2.e091917.37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12968-022-00846-4","article-title":"Precision measurement of cardiac structure and function in cardiovascular magnetic resonance using machine learning","volume":"24","author":"Davies","year":"2022","journal-title":"J Cardiovasc Magn Reson"},{"key":"2025120619231242000_15.2.e091917.38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s11897-023-00636-8","article-title":"Your Heart Function Has Normalized\u2014What Next After TRED-HF?","volume":"20","author":"Kasiakogias","year":"2023","journal-title":"Curr Heart Fail Rep"},{"key":"2025120619231242000_15.2.e091917.39","unstructured":"TRED-HF2 . Health research authority. Available: https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/application-summaries\/research-summaries\/tred-hf2\/ [Accessed 13 Mar 2024]."},{"key":"2025120619231242000_15.2.e091917.40","doi-asserted-by":"crossref","first-page":"966537","DOI":"10.3389\/fcvm.2022.966537","article-title":"Maintenance of recovered dilated cardiomyopathy patients with half-dose neurohumoral blockades (MED-CHARM): A protocol for an open-label, pilot, randomized trial","volume":"9","author":"Li","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2025120619231242000_15.2.e091917.41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaccao.2024.01.009","article-title":"Withdrawal of Neurohormonal Antagonists in Breast Cancer Patients With Cardiotoxicity and Improved Left Ventricular Function","volume":"6","author":"Yu","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2025120619231242000_15.2.e091917.42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.058457"},{"key":"2025120619231242000_15.2.e091917.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.03.462"},{"key":"2025120619231242000_15.2.e091917.44","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037934"},{"key":"2025120619231242000_15.2.e091917.45","unstructured":"The STOP-MED CTRCD . Trial - full text view - clinicaltrials.gov. Available: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06183437?term=stop+med&draw=2&rank=1 [Accessed 13 Mar 2024]."},{"key":"2025120619231242000_15.2.e091917.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2020.09.039"},{"key":"2025120619231242000_15.2.e091917.47","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2019-316297"},{"key":"2025120619231242000_15.2.e091917.48","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/eurheartj\/ehac035","article-title":"Improving cardiovascular magnetic resonance access in low- and middle-income countries for cardiomyopathy assessment: rapid cardiovascular magnetic resonance","volume":"43","author":"Menacho","year":"2022","journal-title":"Eur Heart J"},{"key":"2025120619231242000_15.2.e091917.49","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2589-7500(20)30267-3","article-title":"Diagnosis and risk stratification in hypertrophic cardiomyopathy using machine learning wall thickness measurement: a comparison with human test-retest performance","volume":"3","author":"Augusto","year":"2021","journal-title":"Lancet Digit Health"},{"key":"2025120619231242000_15.2.e091917.50","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023849"},{"key":"2025120619231242000_15.2.e091917.51","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025120619231242000_15.2.e091917.52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11764-023-01336-x","article-title":"Psychosocial experiences of breast cancer survivors: a meta-review","volume":"18","author":"King","year":"2024","journal-title":"J Cancer Surviv"},{"key":"2025120619231242000_15.2.e091917.53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2011.01291.x"},{"key":"2025120619231242000_15.2.e091917.54","unstructured":"James Lind Alliance . Living with and beyond cancer top 10. Available: https:\/\/www.jla.nihr.ac.uk\/priority-setting-partnerships\/living-with-and-beyond-cancer\/top-10-priorities.htm [Accessed 11 Jan 2022]."},{"key":"2025120619231242000_15.2.e091917.55","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00952-0"},{"key":"2025120619231242000_15.2.e091917.56","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.114.001240"},{"key":"2025120619231242000_15.2.e091917.57","first-page":"665","article-title":"\u2018You say treatment, I say hard work\u2019: treatment burden among people with chronic illness and their carers in Australia","volume":"21","author":"Sav","year":"2013","journal-title":"Health Soc Care Community"},{"key":"2025120619231242000_15.2.e091917.58","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00457-7"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-091917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:23:33Z","timestamp":1765077813000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-091917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,5]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bmjopen-2024-091917"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-091917","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}